New research from prostate and bladder cancer Panoramic datasets reveals gaps in treatment implementation, offering pathways for optimized patient-centered care in a rapidly evolving treatment landscape.
Flatiron Health today announced its presence at the American Society of Genitourinary Cancers Symposium happening from February 26-28, 2026, in San Francisco, California. Flatiron's real-world data and research capabilities are featured across multiple presentations, including 6 research acceptances spanning genitourinary cancers.
A cornerstone of Flatiron’s presence at ASCO GU 2026 is the global prostate cancer and bladder cancer Panoramic datasets, which draw from over 420,000 relevant longitudinal patient records in Flatiron’s network. The prostate datasets specifically unlock high-quality, source-level unstructured and structured EHR data across Germany, the UK, and the US. Built on a common data model across all regions, these datasets enable unprecedented interoperability—allowing researchers to seamlessly analyze patient outcomes and treatment patterns across markets to inform global evidence strategies.
"Recent advancements have fundamentally transformed treatment options for genitourinary cancers, but our research reveals a critical gap: too many patients—particularly those with platinum-ineligibility, non-BRCA mutations, or comorbidities—are not benefiting from these breakthroughs," said Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health. "Our ASCO GU research, spanning disease states, biomarker status, and treatment types, illuminates how to translate innovation into practice. By capturing this real-world complexity at scale through our Panoramic Database, we're generating the evidence needed to guide clinicians in a rapidly evolving treatment landscape—enabling them to deliver personalized medicine to any patient that is in front of them.”
Research highlights include:
-
A study demonstrating the need for broader genetic testing and more equitable access to PARP inhibitors for all patients with DNA repair mutations, not just BRCAm carriers, to improve outcomes in advanced prostate cancer
-
A study suggesting that selected cisplatin-ineligible patients with muscle-invasive bladder cancer may benefit from chemotherapy despite medical limitations
-
A study revealing a critical need for more effective therapy options following Lu177, a treatment recently approved for metastatic castration-resistant prostate cancer
Join Flatiron Health at booth #26 Follow Flatiron Health on X and LinkedIn for more updates from #ASCOGU26.
Abstracts and Poster Presentations
Beyond BRCA: Real-world outcomes with poly(ADP-ribose) polymerase inhibitors among patients with metastatic castration-resistant prostate cancer and homologous recombination repair mutations
Eunice A. Hankinson, Brendan T. Kerr, Patrick Ward, Khilna Patel, Samantha Reiss, Aaron Dolor, Michael Curry, Emily Castellanos
Abstract Number: 89
Poster Board Number: B22
Session Title: Poster Session A: Prostate Cancer
Date and Time: February 26, 2026, 11:30 AM-12:45 PM; 5:45 PM-6:45 PM (PST)
Persistent gaps in BRCA mutation testing among mCRPC patients: Insights from US cancer practices (2018–2024)
Rana R. McKay, Weiyan Li, James Roose, Brendan T. Kerr, Smriti Karwa, Chinelo Orji, Nina Yeh, Theresa Cain, Jean H.E. Yong, Kumar Mukherjee
Author Affiliations: University of California San Diego, AstraZeneca, Merck & Co, Flatiron Health
Abstract Number: 102
Poster Board Number: C9
Session Title: Poster Session A: Prostate Cancer
Date and Time: February 26, 2026, 11:30 AM-12:45 PM; 5:45 PM-6:45 PM (PST)
Treatment Patterns and Survival Outcomes Among Lutetium 177 - Experienced Patients with Metastatic Castration-Resistant Prostate Cancer
Ben Tran, Tanya Dorff, Madeline Richey, Eunice Hankinson, Patrick Olsen, Smriti Karwa, Jason Sharpe, Megan Braunlin, Christopher Kim
Author Affiliations: Peter Mac, City of Hope, Amgen, Flatiron Health
Abstract Number: 69
Poster Board Number: B2
Session Title: Poster Session A: Prostate Cancer
Date and Time: February 26, 2026, 11:30 AM-12:45 PM; 5:45 PM-6:45 PM (PST)
Real-world (rw) first-line (1L) treatment (tx) patterns and overall survival (rwOS) in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) with frailty or comorbidities
Enrique Grande, Aristotelis Bamias, Ronald de Wit, Syed Hussain, Constance Thibault, Mairead Kearney, Jason Hoffman, Valerie Morris, Li Chen, James Roose, Eunice Hankinson, Leonardo Crama, Julie Telliez, Joaquim Bellmunt
Author Affiliations: Quironsalud Madrid, National & Kapodistrian University of Athens, Erasmus MC Cancer Institute, University of Sheffield, Université Paris Cité, Merck KGaA, EMD Serono, Roche, Dana-Farber Cancer Institute, Flatiron Health
Abstract Number: 666
Poster Board Number: C16
Session Title: Poster Session B: Prostate Cancer and Urothelial Carcinoma
Date and Time: February 27, 2026, 11:30 AM-12:45 PM; 4:45 PM-5:45 PM (PST)
Real-world neoadjuvant therapy utilization and outcomes in patients with muscle-invasive bladder cancer ineligible for cisplatin treatment
Khilna Patel, Danni Zhao, Eunice Hankinson, Prakirthi Yerram, Aashay Mahesh Mehta, Emily Castellanos
Abstract Number: 672
Poster Board Number: C22
Session Title: Poster Session B: Prostate Cancer and Urothelial Carcinoma
Date and Time: February 27, 2026, 11:30 AM-12:45 PM; 4:45 PM-5:45 PM (PST)
Opportunities for Precision Oncology: Real-world Patterns and Disparities in FGFR3 Testing Among US Patients with Locally Advanced/Metastatic Urothelial Cancer (LA/mUC)
Emily Nash Smyth, Madeline Richey, Khilna Patel, Alan Brnabic, Nada Boualam, Sarah Reid, Ronac Mamtani
Author Affiliations: Eli Lilly and Company, Abramson Cancer Center, Flatiron Health
Abstract Number: 682
Poster Board Number: D6
Session Title: Poster Session B: Prostate Cancer and Urothelial Carcinoma
Date and Time: February 27, 2026, 11:30 AM-12:45 PM; 4:45 PM-5:45 PM (PST)
About Flatiron Health
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
